http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019125154-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8b382763b9993175cf1ec57dfae5f54 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 |
| filingDate | 2018-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8eaa2689baf9ac045d9a25e5f448ee02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90165b500db8c631f5d311a229617255 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fce1b5ec4e5a5728167fc230cf55b8ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21c921f66531d85976005b8747e3cd76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b084b2d40fe798faf6c807d89f7048b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd84dbaecc80d658fbd43ff8395414e7 |
| publicationDate | 2019-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019125154-A3 |
| titleOfInvention | Transition metal-based functional moieties for preparing cell targeting conjugates |
| abstract | The present invention relates to secondary functional moieties comprising a transition metal-based linker and a primary functional moiety bound thereto. The secondary functional moieties according to the present invention comprise a transition metal complex, such as a cis-platinum(ll) complex, which complex has a primary functional moiety (e.g. an unmodified or modified cytotoxic drug) as a first ligand and iodide, bromide or chloride as a second ligand. It has been found that secondary functional moieties comprising an iodide or bromide group as a leaving ligand, in particular an iodide group as a leaving ligand, show an even improved binding efficiency to cell binding moieties (e.g. antibodies). Furthermore, the secondary functional moieties containing iodide or bromide as a leaving ligand are hydrolytically considerably more stable compared with secondary functional moieties containing chloride as a leaving ligand. The invention also relates to cell targeting conjugates comprising a linker of the invention. The present invention further relates to a medicament comprising said cell targeting conjugate and to the use of the cell targeting conjugates in the diagnosis and treatment of cancer. |
| priorityDate | 2017-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.